Abstract
Usually, wherever breast STAT5a is present, PRLR is reduced; without STAT5a PRLR becomes abundant. Five breast lesions essentially lacking both were tested immunohistochemically for PRLR isoforms. The intermediate isoform was essentially only detected in these lesions. In some breast lesions PRLR isoforms may be involved in JAK/STAT pathway disturbances.
Keywords: Breast, STAT5a, PRLR, Immunohistochemistry, Intermediate Isoform
Protein & Peptide Letters
Title: Cells with Minimal Expression of the JAK/STAT Pathway Related Proteins STAT5a and the Prolactin Receptor: Evidence of an Alternate Prolactin Receptor Isoform in Breast Disease
Volume: 17 Issue: 1
Author(s): G. L. Bratthauer, M. D. Stamatakos and T. N. Vinh
Affiliation:
Keywords: Breast, STAT5a, PRLR, Immunohistochemistry, Intermediate Isoform
Abstract: Usually, wherever breast STAT5a is present, PRLR is reduced; without STAT5a PRLR becomes abundant. Five breast lesions essentially lacking both were tested immunohistochemically for PRLR isoforms. The intermediate isoform was essentially only detected in these lesions. In some breast lesions PRLR isoforms may be involved in JAK/STAT pathway disturbances.
Export Options
About this article
Cite this article as:
Bratthauer L. G., Stamatakos D. M. and Vinh N. T., Cells with Minimal Expression of the JAK/STAT Pathway Related Proteins STAT5a and the Prolactin Receptor: Evidence of an Alternate Prolactin Receptor Isoform in Breast Disease, Protein & Peptide Letters 2010; 17 (1) . https://dx.doi.org/10.2174/092986610789909467
DOI https://dx.doi.org/10.2174/092986610789909467 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Potential Applications of Induced Pluripotent Stem Cells (iPSCs) in the Modeling of Gastrointestinal Disorders
Current Stem Cell Research & Therapy Genomic Instability and Carcinogenesis: An Update
Current Genomics Liposomal Nanotechnology for Cancer Theranostics
Current Medicinal Chemistry The Role of ABC and SLC Transporters in the Pharmacokinetics of Dietary and Herbal Phytochemicals and their Interactions with Xenobiotics
Current Drug Metabolism Neuroprotective Effects of Non-Classical Estrogen-Like Signaling Activators: from Mechanism to Potential Implications
CNS & Neurological Disorders - Drug Targets Gold Nanostructures as Photothermal Therapy Agent for Cancer
Anti-Cancer Agents in Medicinal Chemistry Quantificational Methylation Analysis of APC and AXIN2 in HBV-related Hepatocellular Carcinoma
Current Cancer Therapy Reviews Engineered Liposomes for Drug Delivery and Biomedical Imaging
Recent Patents on Nanomedicine Cardiovascular Effects of the Phytoestrogen Genistein
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Prediction of Acridinones’ Ability to Interstrand DNA Crosslinks Formation Using Connected QSRR and QSAR Analysis
Letters in Drug Design & Discovery DNA Repair Pathways and Human Metastatic Malignant Melanoma
Current Molecular Medicine The Design of Amphiphilic Polymeric Micelles of Curcumin for Cancer Management
Current Medicinal Chemistry Progress of CDK4/6 Inhibitor Palbociclib in the Treatment of Cancer
Anti-Cancer Agents in Medicinal Chemistry Radiolabeled Oligonucleotides for Antisense Imaging
Current Organic Synthesis Estrogen Receptor: Structural Differences and Potential Implications on Selectivity Examined by the GRID/CPCA Approach
Letters in Drug Design & Discovery Harmine Induces Gastric Cancer Cell Apoptosis through the ROSmediated PI3K/AKT Signaling Pathway
Current Signal Transduction Therapy Growth Factors in the Pathogenesis of Retinal Neurodegeneration in Diabetes Mellitus
Current Neuropharmacology PCL/PEG Copolymeric Nanoparticles: Potential Nanoplatforms for Anticancer Agent Delivery
Current Drug Targets Patent Selections
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Liposomes as Anticancer Therapeutic Drug Carrier’s Systems: More than a Tour de Force
Current Nanomedicine